Evidence map›Paper›PMID 42948378›Full record

ReviewFrontiers in microbiology2026

From dietary exposure to organ injury: microbiome-mediated biotransformation of food-chain xenobiotics across the gut-liver-kidney axis.

Guolin Li, Yu Xiong, Xixuan Yu, Jiangping Yu, Ruiling Xu

Abstract readReview
In one paragraph

Review in Frontiers in microbiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Guolin Li *Department of Pharmacy, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Yu Xiong *Department of Pharmacy, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Xixuan YuDepartment of Pharmacy, Sichuan First Hospital of Traditional Chinese Medicine, Chengdu, Sichuan, China.
Jiangping YuDepartment of Pharmacy, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.
Ruiling XuNHC Key Laboratory of Nuclear Technology Medical Transformation, Mianyang Central Hospital, School of Medicine, University of Electronic Science and Technology of China, Mianyang, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Food-chain xenobiotics reach the intestine through food additives, processing-generated chemicals, environmental contaminants, and naturally occurring toxins. Their biological effects depend not only on intake but also on microbial metabolism and host handling. Gut microorganisms can detoxify parent compounds or generate metabolites with altered biological activity, while xenobiotic exposure can reshape microbial communities and host-microbial interactions. This review synthesizes evidence on these processes across the gut-liver-kidney axis, with particular attention to metabolic dysfunction-associated steatotic liver disease and chronic kidney disease. We examine direct microbial biotransformation alongside exposure-related changes in intestinal barrier function, immune responses, and metabolic signaling. The resulting synthesis highlights compound-specific and host-specific responses, shaped by microbial enzyme capacity, dietary context, barrier integrity, and hepatic and renal clearance. Impaired organ function can, in turn, alter microbial ecology and promote metabolite accumulation, creating bidirectional interactions between exposure and disease. Although experimental studies provide mechanistic insights, human evidence establishing causal links between dietary xenobiotics, microbial transformation, and chronic liver or kidney injury remains limited. We also evaluate the potential of integrated biomarkers, dietary interventions, and microbial enzyme-targeting strategies, identifying the evidence needed for clinical translation. Future progress requires longitudinal cohorts and controlled dietary studies that combine measured exposure, microbial function, metabolite profiles, and organ-specific outcomes. This integrated perspective provides a framework for investigating individual susceptibility to dietary xenobiotics and evaluating microbiome-informed approaches to food safety and nutrition.

Indexed as

chronic kidney diseasefood-chain xenobioticsgut-liver-kidney axisgut microbiotametabolic dysfunction-associated steatotic liver diseasemicrobial biotransformation

Identifiers

PMID42948378
PMCPMC13712326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.